IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
-11.66%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$225M
AUM Growth
+$225M
(-13%)
Cap. Flow
-$11.9M
Cap. Flow
% of AUM
-5.31%
Top 10 Holdings %
Top 10 Hldgs %
40.28%
Holding
79
New
29
Increased
12
Reduced
7
Closed
30
Top Buys
| 1 |
Merck
MRK
|
$10M |
| 2 |
AstraZeneca
AZN
|
$8.49M |
| 3 |
CTLT
CATALENT, INC.
CTLT
|
$7.79M |
| 4 |
Encompass Health
EHC
|
$7.36M |
| 5 |
LHCG
LHC Group LLC
LHCG
|
$7.01M |
Top Sells
| 1 |
Agilent Technologies
A
|
$14.5M |
| 2 |
DexCom
DXCM
|
$13.1M |
| 3 |
AMED
Amedisys
AMED
|
$10.9M |
| 4 |
Sanofi
SNY
|
$9.54M |
| 5 |
VAR
Varian Medical Systems, Inc.
VAR
|
$8.52M |
Sector Composition
| 1 | Healthcare | 89.53% |
| 2 | Energy | 3.12% |
| 3 | Consumer Discretionary | 1.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Medtronic
MDT
$119B
| $10.4M | 4.57% | 115,000 +10,000 | +10% | +$902K |
|
2
Centene
CNC
$14.3B
| $10.1M | 4.45% | 170,000 +45,000 | +36% | +$2.67M |
|
|
3
Merck
MRK
$210B
| $10M | 4.41% | +130,000 | New | +$10M |
|
4
Bristol-Myers Squibb
BMY
$96B
| $9.76M | 4.3% | 175,000 -15,000 | -8% | -$836K |
|
5
Quest Diagnostics
DGX
$20.3B
| $9.64M | 4.24% | 120,000 +40,000 | +50% | +$3.21M |
|
6
BioMarin Pharmaceuticals
BMRN
$11.2B
| $9.3M | 4.09% | 110,000 | – | – |
|
|
7
AstraZeneca
AZN
$248B
| $8.49M | 3.74% | +190,000 | New | +$8.49M |
|
|
CTLT
8
DELISTED
CATALENT, INC.
CTLT
| $7.79M | 3.43% | +150,000 | New | +$7.79M |
|
|
CCXI
9
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.63M | 3.36% | 190,000 +140,000 | +280% | +$5.63M |
|
|
10
Encompass Health
EHC
$12.3B
| $7.36M | 3.24% | +115,000 | New | +$7.36M |
|
|
LHCG
11
DELISTED
LHC Group LLC
LHCG
| $7.01M | 3.09% | +50,000 | New | +$7.01M |
|
12
Danaher
DHR
$147B
| $6.92M | 3.05% | +50,000 | New | +$6.92M |
|
|
GWPH
13
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $6.57M | 2.89% | 75,000 +55,000 | +275% | +$4.82M |
|
14
Masimo
MASI
$7.59B
| $6.2M | 2.73% | +35,000 | New | +$6.2M |
|
15
Novartis
NVS
$245B
| $5.77M | 2.54% | +70,000 | New | +$5.77M |
|
16
Becton Dickinson
BDX
$55.3B
| $5.74M | 2.53% | +25,000 | New | +$5.74M |
|
17
Agios Pharmaceuticals
AGIO
$2.19B
| $5.32M | 2.34% | 150,000 -40,000 | -21% | -$1.42M |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $4.88M | 2.15% | 170,000 +50,000 | +42% | +$1.44M |
|
19
Exact Sciences
EXAS
$8.98B
| $4.64M | 2.04% | +80,000 | New | +$4.64M |
|
|
ARNA
20
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.62M | 2.04% | 110,000 +40,000 | +57% | +$1.68M |
|
21
Boston Scientific
BSX
$156B
| $4.08M | 1.8% | 125,000 -75,000 | -38% | -$2.45M |
|
|
NVRO
22
DELISTED
NEVRO CORP.
NVRO
| $4M | 1.76% | +40,000 | New | +$4M |
|
23
Dentsply Sirona
XRAY
$2.85B
| $3.88M | 1.71% | +100,000 | New | +$3.88M |
|
24
Cytokinetics
CYTK
$4.23B
| $3.77M | 1.66% | +320,000 | New | +$3.77M |
|
25
Chewy
CHWY
$16.9B
| $3.75M | 1.65% | +100,000 | New | +$3.75M |
|